cenacitinib adipate

Cenacitinib adipate (VTX-958 adipate) is an orally bioavailable, highly selective, and potent allosteric inhibitor of tyrosine kinase 2 (TYK2). Developed by Ventyx Biosciences (which was acquired by Eli Lilly in 2026), it targets the pseudokinase (JH2) domain of TYK2 to selectively inhibit downstream signaling of cytokines such as IL-12, IL-23, and Type I interferons, which are key drivers of chronic inflammation. The adipate salt formulation was specifically evaluated in a Phase 1 study comparing modified-release tablet prototypes against standard film-coated tablets to optimize pharmacokinetics, safety, and tolerability. Although cenacitinib was advanced into Phase 2 clinical trials for moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease, development was terminated across these indications due to insufficient efficacy compared to internal targets and competitors.

Other names

cenacitinib